Barclays PLC Sells 14,150 Shares of Inspire Medical Systems, Inc. (NYSE:INSP)

Barclays PLC lessened its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 33.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,375 shares of the company's stock after selling 14,150 shares during the period. Barclays PLC owned about 0.09% of Inspire Medical Systems worth $5,260,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. First Horizon Advisors Inc. raised its stake in shares of Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock worth $26,000 after purchasing an additional 124 shares during the last quarter. Huntington National Bank grew its holdings in Inspire Medical Systems by 228.3% during the fourth quarter. Huntington National Bank now owns 174 shares of the company's stock worth $32,000 after buying an additional 121 shares in the last quarter. Harbour Investments Inc. raised its position in Inspire Medical Systems by 101.0% in the 4th quarter. Harbour Investments Inc. now owns 197 shares of the company's stock valued at $37,000 after buying an additional 99 shares during the last quarter. AlphaQuest LLC lifted its stake in Inspire Medical Systems by 7,275.0% during the 4th quarter. AlphaQuest LLC now owns 295 shares of the company's stock valued at $55,000 after acquiring an additional 291 shares in the last quarter. Finally, Quadrant Capital Group LLC boosted its holdings in Inspire Medical Systems by 61.9% during the 4th quarter. Quadrant Capital Group LLC now owns 327 shares of the company's stock worth $61,000 after acquiring an additional 125 shares during the last quarter. Institutional investors own 94.91% of the company's stock.

Analyst Ratings Changes

INSP has been the subject of several analyst reports. Truist Financial lowered their target price on shares of Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating for the company in a report on Tuesday, February 11th. Piper Sandler decreased their price objective on shares of Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a research note on Monday, February 10th. Stifel Nicolaus dropped their target price on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. Morgan Stanley reduced their target price on Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating for the company in a report on Tuesday, February 11th. Finally, KeyCorp decreased their price target on Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $218.90.

Inspire Medical Systems Price Performance

Shares of NYSE INSP traded down $1.50 during trading on Wednesday, reaching $158.43. 378,338 shares of the stock traded hands, compared to its average volume of 581,428. The company has a 50-day moving average of $162.08 and a 200-day moving average of $180.56. Inspire Medical Systems, Inc. has a 52-week low of $123.00 and a 52-week high of $257.40. The stock has a market capitalization of $4.71 billion, a P/E ratio of 91.58, a price-to-earnings-growth ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. Analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CTO John Rondoni sold 583 shares of the firm's stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total value of $99,395.67. Following the completion of the transaction, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Randy Ban sold 25,584 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the sale, the insider now directly owns 7,259 shares in the company, valued at $1,332,026.50. This trade represents a 77.90 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.